Last update 21 May 2024

Adalimumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Adalimumab (Genetical Recombination), Raheara, ABT-D2E7
+ [7]
Target
Mechanism
TNF-α inhibitors(Tumor necrosis factor α inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (31 Dec 2002),
RegulationPriority Review (CN), Overseas New Drugs Urgently Needed in Clinical Settings (CN)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D02597Adalimumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pyoderma Gangrenosum
JP
27 Nov 2020
Pustular psoriasis
JP
23 Mar 2018
Behcet Syndrome
JP
17 Jun 2016
Psoriasis vulgaris
JP
17 Jun 2016
Colitis, Ulcerative
AU
10 Dec 2003
Enthesitis-Related Arthritis
AU
10 Dec 2003
Hidradenitis Suppurativa
AU
10 Dec 2003
Polyarticular Juvenile Idiopathic Arthritis
AU
10 Dec 2003
Psoriasis
AU
10 Dec 2003
Juvenile Arthritis
EU
08 Sep 2003
Juvenile Arthritis
IS
08 Sep 2003
Juvenile Arthritis
LI
08 Sep 2003
Juvenile Arthritis
NO
08 Sep 2003
Pediatric Crohn's Disease
EU
08 Sep 2003
Pediatric Crohn's Disease
IS
08 Sep 2003
Pediatric Crohn's Disease
LI
08 Sep 2003
Pediatric Crohn's Disease
NO
08 Sep 2003
Plaque psoriasis
EU
08 Sep 2003
Plaque psoriasis
IS
08 Sep 2003
Plaque psoriasis
LI
08 Sep 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Generalized Pustular PsoriasisPhase 3-28 Sep 2015
Oral UlcerPhase 3
US
01 May 2014
Oral UlcerPhase 3
AT
01 May 2014
Oral UlcerPhase 3
BE
01 May 2014
Oral UlcerPhase 3
CA
01 May 2014
Oral UlcerPhase 3
CZ
01 May 2014
Oral UlcerPhase 3
DK
01 May 2014
Oral UlcerPhase 3
FR
01 May 2014
Oral UlcerPhase 3
DE
01 May 2014
Oral UlcerPhase 3
HU
01 May 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
51
tjlgbfvnkb(jsfuxbmvie) = rddudqjhzf eozvlldruk (fzwrbeqnrb )
-
11 Oct 2023
tjlgbfvnkb(jsfuxbmvie) = dkpuvuxrgl eozvlldruk (fzwrbeqnrb )
Not Applicable
-
fejkfwukdw(hiwbeczamr) = A near-complete response was achieved without adverse events (AEs) for the last 6 months mhmlqskyff (vlfwhzqtyn )
-
11 Oct 2023
Not Applicable
Hidradenitis Suppurativa
TNF-alpha inhibitor Adalimumab
56
Adalimumab 40mg weekly
sybpgdyzlh(xzwotzrqfp) = voqsrojdxs nflnoqddcf (uvfmvkxssq )
Negative
11 Oct 2023
Not Applicable
37
yifsdbclzw(veapqvcknl) = 5 patients discontinued treatment due to severe injection site pain mypebjwpit (zbgatbsrvq )
-
03 Jul 2023
Not Applicable
15
sblcndrquq(efjdvpfevu) = ifkwuzlytl zxihiwmjlm (wqsmqvylow )
Positive
01 Jun 2023
Not Applicable
21
odmzmjplld(uxvzlsoiud) = a case of generalized adenopathy was observed evkxghhpkd (icfmlwbzgv )
-
31 May 2023
Not Applicable
378
Originator Adalimumab (Humira)
prwzetczpl(vhbpcxewyo) = ojdyauvntn xoxzcrkqbg (nfxekgwntz )
-
31 May 2023
Biosimilar Adalimumab (Hyrimoz)
prwzetczpl(vhbpcxewyo) = tdbtabzaua xoxzcrkqbg (nfxekgwntz )
Not Applicable
-
Adalimumab (ADA)
enbqavrowi(mkqzrshyjc) = Adverse event incidence was comparable between the two groups (ADA vs. TCZ: 38.10% vs. 47.37%) qeywfnxvxx (wsoevaxqpz )
Positive
31 May 2023
Tocilizumab (TCZ)
Not Applicable
343
uyiejunnxp(fhfwoxitgw) = voaownvccz zrcbgomlew (lcbnhlxcgv )
Positive
31 May 2023
Phase 4
11
abejjwdxap(stiyvgrwyq) = oophhmxqyd bypjfcever (xoncaziwpq, zlajrbyxtb - zjgisrvsts)
-
08 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free